Altimmune Statistics

Total Valuation

Altimmune has a market cap or net worth of EUR 442.49 million. The enterprise value is 274.87 million.

Market Cap	442.49M
Enterprise Value	274.87M

Important Dates

The next estimated earnings date is Thursday, February 26, 2026.

Earnings Date	Feb 26, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	104.34M
Shares Outstanding	n/a
Shares Change (YoY)	+17.16%
Shares Change (QoQ)	+9.75%
Owned by Insiders (%)	0.66%
Owned by Institutions (%)	40.02%
Float	103.65M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	25,958.80
PB Ratio	2.80
P/TBV Ratio	2.80
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-3.84
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.86

Financial Position

The company has a current ratio of 17.18, with a Debt / Equity ratio of 0.09.

Current Ratio	17.18
Quick Ratio	16.83
Debt / Equity	0.09
Debt / EBITDA	n/a
Debt / FCF	-0.24
Interest Coverage	-118.87

Financial Efficiency

Return on equity (ROE) is -52.61% and return on invested capital (ROIC) is -33.59%.

Return on Equity (ROE)	-52.61%
Return on Assets (ROA)	-30.87%
Return on Invested Capital (ROIC)	-33.59%
Return on Capital Employed (ROCE)	-43.95%
Revenue Per Employee	289
Profits Per Employee	-1.21M
Employee Count	59
Asset Turnover	0.00
Inventory Turnover	n/a

Taxes

Income Tax	-580,416
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -44.81% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-44.81%
50-Day Moving Average	3.52
200-Day Moving Average	4.08
Relative Strength Index (RSI)	63.73
Average Volume (20 Days)	148

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	8.22

Income Statement

In the last 12 months, Altimmune had revenue of EUR 17,046 and -71.52 million in losses. Loss per share was -0.90.

Revenue	17,046
Gross Profit	-57.77M
Operating Income	-77.10M
Pretax Income	-72.10M
Net Income	-71.52M
EBITDA	-77.00M
EBIT	-77.10M
Loss Per Share	-0.90

Full Income Statement

Balance Sheet

The company has 179.64 million in cash and 13.56 million in debt, giving a net cash position of 166.09 million.

Cash & Cash Equivalents	179.64M
Total Debt	13.56M
Net Cash	166.09M
Net Cash Per Share	n/a
Equity (Book Value)	158.19M
Book Value Per Share	1.65
Working Capital	173.88M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -56.55 million and capital expenditures -8,523, giving a free cash flow of -56.56 million.

Operating Cash Flow	-56.55M
Capital Expenditures	-8,523
Free Cash Flow	-56.56M
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	-452,310.00%
Pretax Margin	-422,980.00%
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Altimmune does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-17.16%
Shareholder Yield	-17.16%
Earnings Yield	-16.16%
FCF Yield	-12.78%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on September 14, 2018. It was a reverse split with a ratio of 0.0333333333.

Last Split Date	Sep 14, 2018
Split Type	Reverse
Split Ratio	0.0333333333

Scores

Altimmune has an Altman Z-Score of 3.82 and a Piotroski F-Score of 2.

Altman Z-Score	3.82
Piotroski F-Score	2